Wel­come Case­bia, the $335M gene edit­ing JV hatched by Bay­er and CRISPR Ther­a­peu­tics

The new gene edit­ing joint ven­ture be­ing formed by Bay­er and CRISPR Ther­a­peu­tics is tak­ing shape. Now dubbed Case­bia Ther­a­peu­tics, the fledg­ling op­er­a­tions has be­gun hir­ing dozens of new staffers, tak­ing up a tem­po­rary res­i­dence while its new home is be­ing built in Kendall Square in Cam­bridge, MA.

The up­start biotech ef­fort just inked a lease on 33,000 square feet of space at 610 Main Street North, a nine-sto­ry build­ing cur­rent­ly un­der con­struc­tion near Kendall Square and ad­ja­cent to the MIT cam­pus. This is the sec­ond MIT-owned build­ing here, with Pfiz­er R&D oc­cu­py­ing the first. The com­pa­ny will be co-lo­cat­ed with CRISPR Ther­a­peu­tics’ R&D ops in the cen­ter of a thriv­ing biotech clus­ter that will be home for up to 80 staffers, while an­oth­er group will be lo­cat­ed in Bay­er’s Mis­sion Bay cam­pus in San Fran­cis­co.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER